^
Association details:
| Biomarker: | EGFR exon 20 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Published date:
04/05/2022
Excerpt:
We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres….PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036).
DOI:
https://doi.org/10.1007/s00432-022-03984-5
Source:
Title:
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.
Published date:
12/10/2021
Excerpt:
We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib….OS of all patients was 21.4 months (95%CI: 16.1-26.6), while PFS was 7.2 months (95%CI: 5.1-9.3). When PFS and OS were compared according to the type of TKI used, PFS was 8.0 months (95%CI: 4.7-11.3) in the erlotinib arm and 7.0 months (95%CI: 4.4-9.6) in the afatinib arm.
DOI:
10.21203/rs.3.rs-1125056/v1
Source:
Title:
Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy.
Published date:
05/16/2018
Excerpt:
We retrospectively analyzed 86 NSCLC patients with EGFR mutations...Two patients with exon 20, Gln787Gln mutations were responsive to erlotinib therapy in the second line setting after first line chemotherapy.
DOI:
10.1200/JCO.2018.36.15_suppl.e21212
